Virological evolution in HIV treatment-experienced patients with raltegravir-based salvage regimens

被引:0
|
作者
Katlama, C. [1 ]
Caby, F. [1 ]
Andrade, R. M. [1 ]
Schneider, L. [1 ]
Canestri, A. [1 ]
Ktroza, N. [1 ]
Tubiana, R. [1 ]
Valantin, M. A. [1 ]
Wirden, M. [2 ]
Mallet, I. [2 ]
Calvez, V. [2 ]
机构
[1] Hop La Pitie Salpetriere, Dept Infect Dis, Paris, France
[2] Hop La Pitie Salpetriere, Dept Virol, Paris, France
关键词
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
引用
收藏
页码:A13 / A13
页数:1
相关论文
共 50 条
  • [41] Profile of darunavir in the management of treatment-experienced HIV patients
    Wolfe, Cameron
    Hicks, Charles
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2009, 1 : 13 - 21
  • [42] Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir
    Flandre, Philippe
    Marcelin, Anne-Genevieve
    Calvez, Vincent
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (04) : 448 - 454
  • [43] Similar Efficacy of Raltegravir When Used With or Without a Protease Inhibitor in Treatment-Experienced Patients
    Skiest, Daniel J.
    Cohen, Calvin
    Mounzer, Karam
    Haigney, Zach
    Barker, David
    Gottlieb, Michael
    Bellman, Paul C.
    Dejesus, Edwin
    Khanlou, Homayoon
    Ruane, Peter J.
    Hsiao, Chiu-Bin
    Abriola, Kenneth
    Rashbaum, Bruce
    Bellos, Nicholaos
    Ward, Douglas
    Colson, Amy
    Santiago, Frances
    Habel, Anne
    Garb, Jane
    HIV CLINICAL TRIALS, 2011, 12 (03): : 131 - 140
  • [44] HIV-DNA VIRAL KINETICS AND THERAPEUTIC DRUG MONITORING DURING RALTEGRAVIR-BASED SALVAGE THERAPY
    Tommasi, C.
    Abbate, I.
    Tempestilli, M.
    Rozera, G.
    Bellagamba, R.
    Pucillo, L. P.
    Capobianchi, M. R.
    Nicastri, E.
    Narciso, P.
    INFECTION, 2009, 37 : 20 - 20
  • [45] Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study
    De La Mata, Nicole L.
    Cooper, David A.
    Russell, Darren
    Smith, Don
    Woolley, Ian
    Sullivan, Maree O.
    Wright, Stephen
    Law, Matthew
    SEXUAL HEALTH, 2016, 13 (04) : 335 - 344
  • [46] No effect of subtype on susceptibility and virological response to TPV/r for treatment-experienced patients
    Bethell, R.
    Hall, D. B.
    Baxter, J.
    Schapiro, J.
    Boucher, C.
    Scherer, J.
    ANTIVIRAL THERAPY, 2008, 13 (04) : A121 - A121
  • [47] Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies
    Canducci, Filippo
    Sampaolo, Michela
    Marinozzi, Maria Chiara
    Boeri, Enzo
    Spagnuolo, Vincenzo
    Galli, Andrea
    Castagna, Antonella
    Lazzarin, Adriano
    Clementi, Massimo
    Gianotti, Nicola
    AIDS, 2009, 23 (04) : 455 - 460
  • [48] HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients
    Falloon, J
    Ait-Khaled, M
    Thomas, DA
    Brosgart, CL
    Eron, JJ
    Feinberg, J
    Flanigan, TP
    Hammer, SM
    Kraus, PW
    Murphy, R
    Torres, R
    Masur, H
    AIDS, 2002, 16 (03) : 387 - 396
  • [49] Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study
    Gazaignes, Sandrine
    Resche-Rigon, Matthieu
    Gatey, Caroline
    Yang, Chloe
    Denis, Blandine
    Fonsart, Julien
    Desseaux, Kristell
    Guionie, Michel
    Rozenbaum, Willy
    Delaugerre, Constance
    Molina, Jean-Michel
    ANTIVIRAL THERAPY, 2016, 21 (04) : 329 - 336
  • [50] Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA
    Rossetti, Barbara
    Meini, Genny
    Bianco, Claudia
    Lamonica, Silvia
    Mondi, Annalisa
    Belmonti, Simone
    Fanti, Iuri
    Ciccarelli, Nicoletta
    Di Giambenedetto, Simona
    Zazzi, Maurizio
    De Luca, Andrea
    JOURNAL OF CLINICAL VIROLOGY, 2017, 91 : 18 - 24